BMJ 1999;318:565-566 ( 27 February )

Papers

Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study

Luis A García Rodríguez, director,  Ana Ruigómez, epidemiologist. 

Centro Español de Investigación Farmaco- epidemiológica, Madrid 28004, Spain

Correspondence to: Dr Rodríguez lagarcia{at}ceife.es

Evidence exists of an increased risk of irritable bowel syndrome after an episode of bacterial gastroenteritis. 1 2 In one study, 12 out of 38 patients presented with bowel dysfunction 1 year after salmonella gastroenteritis.1 In another study, 386 patients with bacterial gastroenteritis were surveyed by questionnaire 6 months after infection, and 27 (7%) had developed irritable bowel syndrome.2 Both studies, however, lacked a control group.3

    Subjects, methods, and results
Top
Subjects, methods, and results
Comment
References

Our source population came from the General Practice Research Database, which contains clinical information on patients recorded by general practitioners in the United Kingdom.4

We identified patients aged 25 to 74 with a bacteriologically confirmed first episode of gastroenteritis, from a recent study that examined the association between acid suppressing drugs and the development of gastroenteritis.5 We excluded all patients with a history of irritable bowel syndrome, cancer, or alcoholism. We sampled a comparison cohort from the source population from which patients with gastroenteritis had been ascertained. We applied the same eligibility criteria as were used for the ascertainment of the gastroenteritis cohort, but the subjects had to be free of gastroenteritis at the start of follow up. We then followed up both cohorts during 1 year until the earliest occurrence of one of the following end points: diagnosis of irritable bowel syndrome, cancer, alcohol misuse, or death. To confirm diagnoses, we sent a questionnaire to the doctors of all patients with irritable bowel syndrome in the gastroenteritis cohort and a 10% random sample (n=216) to the doctors of patients with irritable bowel syndrome in the general population. We used Poisson regression to calculate incidence, relative risk, and 95% confidence intervals of irritable bowel syndrome associated with gastroenteritis. The general population cohort was used as the reference group, and the estimates were adjusted for age, sex, and body mass index.

Our study included 584 308 subjects in the general population cohort and 318 patients in the gastroenteritis cohort (table). During the 1 year follow up, 2027 (0.3%) subjects in the general population cohort and 14 (4.4%) in the gastroenteritis cohort had a diagnosis of irritable bowel syndrome recorded on computer. One hundred and sixty nine subjects (78%) from the random sample of the general population cohort, and 12 (86%) subjects in the gastroenteritis cohort, had confirmed irritable bowel syndrome on the basis of the questionnaire. We analysed all patients in the general population with a diagnosis of irritable bowel syndrome recorded on computer and all cases confirmed by the doctor in the gastroenteritis cohort. The adjusted relative risk of irritable bowel syndrome was much higher in the gastroenteritis cohort than in the general population cohort (difference 11.9, 95% confidence interval 6.7 to 21.0).


                              
View this table:
[in this window]
[in a new window]
 

Characteristics of study cohorts, and incidence and relative risk of irritable bowel syndrome associated with gastroenteritis. Values are numbers (percentages) unless stated otherwise    



    Comment
Top
Subjects, methods, and results
Comment
References

We found that, in the year after an episode of gastroenteritis, patients were 10 times more likely to have irritable bowel syndrome than were subjects in the general population. All incident cases of irritable bowel syndrome in the gastroenteritis cohort were confirmed by the doctor, but we obtained only a random sample of patients with irritable bowel syndrome in the general population owing to the large number of cases (>2000 patients). When we adjusted for this, the incidence of irritable bowel syndrome was reduced to 2.7 per 1000 per year in the general population, and the crude relative risk associated with gastroenteritis was increased to 14.4.

Only one other study has analysed the risk of irritable bowel syndrome in an unselected group of patients with gastroenteritis.2 The authors estimated a rate of newly diagnosed irritable bowel syndrome of about 7%, similar to our finding (4%). Our study, however, is the first to include a control group and therefore to provide estimates of relative risk.3 We conclude that bacterial gastroenteritis is a major independent risk factor for irritable bowel syndrome.

    Acknowledgments

We thank the staff at the Epidemiology and Pharmacology Information Centre, the doctors participating in the general practice research database, and Saga Johansson and Mari-Ann Wallander for providing the initial idea for the study and for commenting on the paper.

Contributors: LAGR designed the study protocol, participated in data analysis, and wrote the paper; he will act as guarantor for the paper. AR helped with data analysis and contributed to the paper.

Funding: None.

Competing interests: Research funds were provided for the original study from which the gastroenteritis cohort was identified.

    References
Top
Subjects, methods, and results
Comment
References

  1. McKendrick MW, Read NW. Irritable bowel syndrome---post salmonella infection. J Infect 1994; 29: 1-3[Medline].
  2. Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis, and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ 1997; 314: 779-782[Abstract/Free Full Text].
  3. Barber R, Blakey A. Prevalence of gastrointestinal symptoms after bacterial gastroenteritis: study did not include control group. BMJ 1997; 314: 1903[Free Full Text].
  4. García Rodríguez LA, Gutthann S. Use of the UK general practice research database for pharmacoepidemiology. Br J Clin Pharmacol 1998; 45: 419-425[Medline].
  5. García Rodríguez LA, Ruigómez A. Gastric acid, acid-suppressing drugs, and bacterial gastroenteritis: how much of a risk? Epidemiology 1997; 8: 571-574[Medline].

(Accepted 30 October 1998)

© BMJ 1999
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Relevant Article

Gastroenteritis greatly increases risk of irritable bowel syndrome
BMJ 1999 318: 0. [Full Text]

This article has been cited by other articles:

  • Spiller, R (2007). Chronic diarrhoea. Gut 56: 1756-1757 [Full text]  
  • Spiller, R, Aziz, Q, Creed, F, Emmanuel, A, Houghton, L, Hungin, P, Jones, R, Kumar, D, Rubin, G, Trudgill, N, Whorwell, P (2007). Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 56: 1770-1798 [Abstract] [Full text]  
  • Spence, M. J, Moss-Morris, R. (2007). The cognitive behavioural model of irritable bowel syndrome: a prospective investigation of patients with gastroenteritis. Gut 56: 1066-1071 [Abstract] [Full text]  
  • Distrutti, E., Sediari, L., Mencarelli, A., Renga, B., Orlandi, S., Russo, G., Caliendo, G., Santagada, V., Cirino, G., Wallace, J. L., Fiorucci, S. (2006). 5-Amino-2-hydroxybenzoic Acid 4-(5-Thioxo-5H-[1,2]dithiol-3yl)-phenyl Ester (ATB-429), a Hydrogen Sulfide-Releasing Derivative of Mesalamine, Exerts Antinociceptive Effects in a Model of Postinflammatory Hypersensitivity. J. Pharmacol. Exp. Ther. 319: 447-458 [Abstract] [Full text]  
  • Moss-Morris, R., Spence, M. (2006). To "Lump" or to "Split" the Functional Somatic Syndromes: Can Infectious and Emotional Risk Factors Differentiate Between the Onset of Chronic Fatigue Syndrome and Irritable Bowel Syndrome?. Psychosom. Med. 68: 463-469 [Abstract] [Full text]  
  • Verdu, E F, Bercik, P, Verma-Gandhu, M, Huang, X-X, Blennerhassett, P, Jackson, W, Mao, Y, Wang, L, Rochat, F, Collins, S M (2006). Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut 55: 182-190 [Abstract] [Full text]  
  • Spiller, R. C. (2005). Irritable bowel syndrome. Br Med Bull 72: 15-29 [Abstract] [Full text]  
  • Wynn, G., Ma, B., Ruan, H. Z., Burnstock, G. (2004). Purinergic component of mechanosensory transduction is increased in a rat model of colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 287: G647-G657 [Abstract] [Full text]  
  • Collins, S M, Barbara, G (2004). East meets West: infection, nerves, and mast cells in the irritable bowel syndrome. Gut 53: 1068-1069 [Full text]  
  • Wang, L-H, Fang, X-C, Pan, G-Z (2004). Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut 53: 1096-1101 [Abstract] [Full text]  
  • Collins, S (2004). Putative therapeutic targets in the treatment of visceral hyperalgesia. Gut 53: ii19-21 [Abstract] [Full text]  
  • Moreels, T G, Nieuwendijk, R J, De Man, J G, De Winter, B Y, Herman, A G, Van Marck, E A, Pelckmans, P A (2004). Concurrent infection with Schistosoma mansoni attenuates inflammation induced changes in colonic morphology, cytokine levels, and smooth muscle contractility of trinitrobenzene sulphonic acid induced colitis in rats. Gut 53: 99-107 [Abstract] [Full text]  
  • Parry, S. D., Corbett, S., James, P. J., Barton, R., Welfare, M. R. (2003). Illness Perceptions in People with Acute Bacterial Gastro-Enteritis. J Health Psychol 8: 693-704 [Abstract]  
  • Gwee, K-A, Collins, S M, Read, N W, Rajnakova, A, Deng, Y, Graham, J C, McKendrick, M W, Moochhala, S M (2003). Increased rectal mucosal expression of interleukin 1{beta} in recently acquired post-infectious irritable bowel syndrome. Gut 52: 523-526 [Abstract] [Full text]  
  • Spanier, J. A., Howden, C. W., Jones, M. P. (2003). A Systematic Review of Alternative Therapies in the Irritable Bowel Syndrome. Arch Intern Med 163: 265-274 [Abstract] [Full text]  
  • Neal, K R, Barker, L, Spiller, R C (2002). Prognosis in post-infective irritable bowel syndrome: a six year follow up study. Gut 51: 410-413 [Abstract] [Full text]  
  • Barbara, G, De Giorgio, R, Stanghellini, V, Cremon, C, Corinaldesi, R (2002). A role for inflammation in irritable bowel syndrome?. Gut 51: i41-44 [Abstract] [Full text]  
  • Asfaha, S., MacNaughton, W. K., Appleyard, C. B., Chadee, K., Wallace, J. L. (2001). Persistent epithelial dysfunction and bacterial translocation after resolution of intestinal inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 281: G635-G644 [Abstract] [Full text]  
  • Bytzer, P, Howell, S, Leemon, M, Young, L J, Jones, M P, Talley, N J (2001). Low socioeconomic class is a risk factor for upper and lower gastrointestinal symptoms: a population based study in 15 000 Australian adults. Gut 49: 66-72 [Abstract] [Full text]  
  • Spiller, R C, Jenkins, D, Thornley, J P, Hebden, J M, Wright, T, Skinner, M, Neal, K R (2000). Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 47: 804-811 [Abstract] [Full text]  
  • Jones, J, Boorman, J, Cann, P, Forbes, A, Gomborone, J, Heaton, K, Hungin, P, Kumar, D, Libby, G, Spiller, R, Read, N, Silk, D, Whorwell, P (2000). British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome. Gut 47: ii1-19 [Full text]  
  • (1999). Bacterial Gastroenteritis Is a Risk Factor for Irritable Bowel. JWatch General 1999: 5-5 [Full text]  

Rapid Responses:

Read all Rapid Responses

Irritable bowel syndrome and gastroenteritis
R A Seaton
bmj.com, 3 Mar 1999 [Full text]
Irritable bowel syndrome after bacterial gastroenteritis
Kenneth W Heaton
bmj.com, 23 Mar 1999 [Full text]
Kept saying I wasn't stressed!
Marie Downes
bmj.com, 29 Mar 1999 [Full text]
Crohn''''s Disease after Salmonella
Eileen Hughes
bmj.com, 11 Aug 1999 [Full text]
Access all current jobs at BMJ Group
Whats new online at Student BMJ
Listen to the latest BMJ Interview